Rabbit Recombinant Monoclonal E3 ubiquitin-protein ligase MUL1 antibody. Carrier free. Suitable for WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
WB | IHC-P | ICC/IF | Flow Cyt (Intra) | IP | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Mouse | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Human, Rat | Dilution info - | Notes - |
Select an associated product type
Exhibits weak E3 ubiquitin-protein ligase activity (By similarity). E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates (By similarity). Can ubiquitinate AKT1 preferentially at 'Lys-284' involving 'Lys-48'-linked polyubiquitination and seems to be involved in regulation of Akt signaling by targeting phosphorylated Akt to proteasomal degradation (By similarity). Mediates polyubiquitination of cytoplasmic TP53 at 'Lys-27' which targets TP53 for proteasomal degradation, thus reducing TP53 levels in the cytoplasm and mitochondrion (By similarity). Proposed to preferentially act as a SUMO E3 ligase at physiological concentrations (By similarity). Plays a role in the control of mitochondrial morphology by promoting mitochondrial fragmentation, and influences mitochondrial localization (By similarity). Likely to promote mitochondrial fission through negatively regulating the mitochondrial fusion proteins MFN1 and MFN2, acting in a pathway that is parallel to the PRKN/PINK1 regulatory pathway (PubMed:24898855). May also be involved in the sumoylation of the membrane fission protein DNM1L (By similarity). Inhibits cell growth (By similarity). When overexpressed, activates JNK through MAP3K7/TAK1 and induces caspase-dependent apoptosis (By similarity). Involved in the modulation of innate immune defense against viruses by inhibiting RIGI-dependent antiviral response (By similarity). Can mediate RIGI sumoylation and disrupt its polyubiquitination (By similarity).
Gide, Mul1, Mitochondrial ubiquitin ligase activator of NFKB 1, E3 ubiquitin-protein ligase MUL1, Growth inhibition and death E3 ligase, Protein Hades, RING-type E3 ubiquitin transferase NFKB 1
Rabbit Recombinant Monoclonal E3 ubiquitin-protein ligase MUL1 antibody. Carrier free. Suitable for WB and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab315225 is the carrier-free version of Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
E3 ubiquitin-protein ligase MUL1 also known as MULAN or MAPL is an important enzyme in cellular processes. It possesses a mass of approximately 45 kDa and functions as an E3 ligase which facilitates the transfer of ubiquitin to specific substrate proteins. This tagging mechanism plays a critical role in directing proteins for degradation through the proteasome pathway. MUL1 is expressed in various tissues including the heart brain and skeletal muscle highlighting its broad biological relevance. As a mitochondrial membrane protein MUL1 helps maintain mitochondrial integrity by targeting specific proteins for ubiquitination.
MUL1 regulates numerous cellular processes such as apoptosis mitophagy and the mitochondrial dynamics by modulating the stability of target proteins. MUL1 operates independently and does not require a specific E2 enzyme for its function. Additionally it participates in cellular homeostasis by mediating the degradation of proteins that impact mitochondrial fusion and fission events. Since MUL1 forms part of the regulatory mechanisms governing cellular adaptation and survival its levels and activity are finely controlled within the cell.
MUL1 is actively involved in the mitophagy and DNA damage response pathways. Its role in the mitophagy pathway links MUL1 to PINK1 and PARKIN proteins that are critical for the removal of damaged mitochondria. In the context of the DNA damage response MUL1 functions to reprogram metabolic pathways yielding protection against cellular stress. This activity associates it with proteins like p53 a well-known tumor suppressor anchoring its presence in mechanisms of cellular defense.
MUL1 presents potential connections to neurodegenerative diseases and cancer. In Parkinson's disease dysfunction in MUL1 activity can disrupt mitochondrial quality control especially when interacting with PINK1 and PARKIN aggravating neuronal damage. Moreover alterations in MUL1 expression can influence cancer progression by impacting the p53 pathway therefore affecting cell cycle and apoptosis regulation. These associations reveal the importance of MUL1's activity for cellular health and its potential as a therapeutic target for disease intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
Exposure time: Lanes 1-2: 180 seconds, lanes 3-8: 125 seconds
All lanes: Western blot - Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] (Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224) at 1/1000 dilution
Lane 1: RD (Human muscle rhabdomyosarcoma) whole cell lysate at 20 µg
Lane 2: A-204 (rat muscle rhabdomyosarcoma) whole cell lysate at 20 µg
Lane 3: PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 4: HL-1 (mouse atrial muscle cell) whole cell lysate at 20 µg
Lane 5: J774A.1 (mouse reticulum cell sarcoma monocyte macrophage) whole cell lysate at 20 µg
Lane 6: RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg
Lane 7: F9 (mouse embryonal carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 8: NMuLi (mouse liver epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Observed band size: 37 kDa, 36 kDa
This data was developed using Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Low expression: thymus (PMID: 18591963).
The lanes 1-5 were developed using a high sensitivity ECL substrate.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
Exposure time: Lanes 1-4: 114 seconds, lane 5: 125 seconds, lanes 6-7: 180 seconds.
All lanes: Western blot - Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] (Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224) at 1/1000 dilution
Lane 1: Mouse liver tissue lysate at 20 µg
Lane 2: Mouse kidney tissue lysate at 20 µg
Lanes 3 - 4: Mouse placenta tissue lysate at 20 µg
Lane 5: Rat liver tissue lysate at 20 µg
Lane 6: Human liver tissue lysate at 20 µg
Lane 7: Human thymus tissue lysate at 20 µg
Lanes 1 - 5: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Lanes 6 - 7: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Observed band size: 37 kDa, 36 kDa
This data was developed using Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] (Anti-E3 ubiquitin-protein ligase MUL1 antibody [EPR27201-55] ab315224) at 1/1000 dilution
Lane 1: HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: HeLa transfected with siRNA specifically targeting E3 ubiquitin-protein ligase MUL1 whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Observed band size: 37 kDa, 36 kDa
Exposure time: 180s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com